文献速递肿瘤 PET/CT放射性药物与辐射防护

成纤维细胞激活蛋白靶向PET在乳腺癌不同组织病理和分子亚型中的摄取:系统综述与Meta分析

Fibroblast activation protein-targeted PET uptake across various histopathological and molecular subtypes of breast cancer: a systematic review and meta-analysis.
PubMed 文献 · Semin Nucl Med · 2026-10-29

原发恶性肿瘤的汇总平均SUVmax为11.74(95%CI:9.95-13.53),FAPI PET较[18F]FDG PET平均高6.19(95%CI:4.26-8.12)。FAPI PET在所有分析的乳腺癌亚型中均显示较高摄取,可能提高病灶显像清晰度和检出率,尤其在[18F]FDG低摄取恶性肿瘤中。

要点

  • FAPI PET原发乳腺癌汇总SUVmax为11.74,较FDG PET平均高6.19。
  • IDC亚型中FAPI PET较FDG PET摄取高11.33(95%CI:8.36-14.30)。
  • Luminal A亚型中FAPI PET较FDG PET摄取高7.85(95%CI:5.45-10.25)。

核心结论

  • FAPI PET在乳腺癌各亚型中显示一致的高半定量摄取,可能提高病灶显像清晰度和检出率,尤其在[18F]FDG低摄取恶性肿瘤中。

研究设计与样本

  • Meta分析使用R软件的meta包进行。

主要发现

  • 原发恶性肿瘤FAPI PET汇总平均SUVmax为11.74(95%CI:9.95-13.53)。
  • 在同时提供FAPI PET和[18F]FDG PET SUVmax的研究中,FAPI PET汇总SUVmax平均较[18F]FDG PET高6.19(95%CI:4.26-8.12)。
  • FAPI PET在所有分析的乳腺癌亚型中均显示较高摄取,汇总估计值范围为10.27至19.99。
  • 在报告IDC亚型两种PET SUVmax的研究中,FAPI PET汇总摄取较[18F]FDG PET高11.33(95%CI:8.36-14.30)。
  • 在报告Luminal A亚型SUVmax的研究中,FAPI PET较[18F]FDG PET摄取高7.85(95%CI:5.45-10.25)。

临床怎么用

  • FAPI PET可用于乳腺癌各亚型的显像评估,尤其在[18F]FDG低摄取恶性肿瘤中可能提高病灶检出率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To conduct a systematic review and meta-analysis on the uptake value of fibroblast activation protein (FAP)-targeted PET (FAPI PET) across different histopathological and molecular breast cancer subtypes. As a secondary objective, to perform head-to-head comparisons with [18F]FDG PET. MATERIALS AND METHODS: This systematic review and meta-analysis was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Major medical literature databases were systematically searched to include studies in which biopsy-proven breast cancer patients were recruited, and uptake values for malignant primary tumors and/or metastatic lesions were reported. Meta-analyses were conducted in R (R Foundation for Statistical Computing, Vienna, Austria) using the meta package. RESULTS: Thirty-four studies met the inclusion criteria. Pooled average SUVmax in the primary malignancy was 11.74 (95%CI:9.95-13.53) on FAPI PET. In the studies in which SUVmax values were provided for both FAPI PET and [18F]FDG PET, on average, the pooled SUVmax was 6.19 (95%CI:4.26-8.12) higher on FAPI PET compared to [18F]FDG PET. FAPI PET showed rather consistently high uptake across all analyzed breast cancer subtypes (pooled estimates ranged from 10.27 to 19.99). Notably, in studies reporting SUVmax for IDC on both FAPI PET and [18F]FDG PET, FAPI PET showed 11.33 (95%CI:8.36-14.30) higher pooled uptake. Similarly, in studies providing SUVmax for luminal A breast cancer, FAPI PET showed 7.85 (95%CI:5.45-10.25) higher uptake compared to [18F]FDG PET. CONCLUSION: Our findings suggest that FAPI PET exhibits consistently high semi-quantitative values across breast cancer subtypes and can potentially enhance lesion conspicuity and detection rate, particularly in low-[18F]FDG-avid malignancies.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Sadeghpour S, Mirshahvalad SA, Askari E, et al. Fibroblast activation protein-targeted PET uptake across various histopathological and molecular subtypes of breast cancer: a systematic review and meta-analysis. Semin Nucl Med. 2026. PMID: 42951722. doi:10.1053/j.semnuclmed.2026.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。